*WENJUN ZHU1, Rinako Tanaka1, Tetsuo Matsuzaki1, Hiroyuki Mizoguchi1, Kaibuchi Kozo5, Ozaki Norio2, Toshitaka Nabeshima4, Taku Nagai3, Kiyofumi Yamada1
(1. Neuropsychopharmacology and Hospital Pharmacy, Graduate school of medicine, Nagoya University, Nagoya,Aichi, Japan, 2. Department of Psychiatry, Nagoya University Graduate School of Medicine, Nag oya, Aichi, Japan, 3. Division of Behavioral Neuropharmacology, International center for brain sci ence, Fujita Health University, Aichi, Japan, 4. Advanced Diagnostic System Research Laboratory Fujita Health University, Gra duate School of Health Sciences & Aino University, Toyoake, Aichi, Japan., 5. Division of Cell Biology, International Center for Brain Science(ICBS), Fuji ta Health University, Aichi, Japan)
Keywords:Phosphoproteomics, Schizophrenia, Cognitive dysfunction, Rho kinase